Results 41 to 50 of about 34,967 (216)
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno +13 more
wiley +1 more source
Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. [PDF]
, 2017 OBJECTIVES Treatment of epistaxis in patients on anticoagulants is challenging and associated with higher admission rates and longer hospital stays compared with patients without anticoagulation. However, there is little information about epistaxis in
Sauter, Thomas +15 more
core +2 more sources
BMC Cardiovascular Disorders, 2017 Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Faye L. Norby +7 more
doaj +1 more source
Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration
BMEMat, EarlyView.The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang +13 more
wiley +1 more source
Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases [PDF]
, 2016 In the therapeutic approach to patients with antiphospholipid syndrome (APS) with thrombotic manifestations, oral vitamin K antagonists (VKA) remain the standard of care.
Marzena Olesińska, Ewa Haładyj
core +1 more source
Pharmaceutics, 2022 Low-dose rivaroxaban has been used in Asian patients with direct oral anticoagulants (DOACs) eligible for atrial fibrillation (AF). However, there are few pharmacokinetic (PK) data in Thai patients to support precise dosing. This study aimed to develop a
Noppaket Singkham +7 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely ...
Yoo Jin Jang +2 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundVenous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for ...
Jay M. Margolis +7 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source